# Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

> **NCT02220907** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 153 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Teneligliptin/Canagliflozin

## Key facts

- **NCT ID:** NCT02220907
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220907, "Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02220907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*